A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs JNJ-63733657 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 20 Aug 2019 Status changed from recruiting to completed.
- 10 Oct 2018 Status changed from not yet recruiting to recruiting.
- 04 Oct 2018 New trial record